Immunex to file Novantrone NDA for hormone refractory prostate cancer in first half of 1996.
IMMUNEX TO FILE NOVANTRONE NDA FOR HORMONE REFRACTORY PROSTATE CANCER in the first half of 1996, Immunex CEO Edward Fritzky forecast Jan. 9 at the Hambrecht & Quist annual health care conference in San Francisco. Novantrone (mitoxantrone) currently is indicated for initial therapy of acute nonlymphocytic leukemia in adults. "In December, we had a favorable discussion with the FDA about our filing plan, and if all goes well with our final data analysis, we plan to file for Novantrone's use in hormone refractory prostate cancer in the first half of this year," Fritzky said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth